Company Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.3787 ^USD	+2.80%		-9.73%	-16.77%

Apr. 04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Number of employees: 6

Managers	Title	Age	Since
Allen Baharaff CEO	Chief Executive Officer	59	99-12-31
Doron Cohen DFI	Director of Finance/CFO	57	22-01-31
Guy Nehemya COO	Chief Operating Officer	39	13-09-30
Liat Hayardeny CTO	Chief Tech/Sci/R&D Officer	57	16-09-06
Yohai Stenzler AUD	Comptroller/Controller/Auditor	41	14-05-31

Members of the board	Title	Age	Since
David Sidransky BRD	Director/Board Member	64	14-05-31
Carol Brosgart BRD	Director/Board Member	72	17-06-06
Allen Baharaff CEO	Chief Executive Officer	59	99-12-31
Shmuel Nir BRD	Director/Board Member	62	06-12-31
Amir Poshinski BRD	Director/Board Member	63	20-06-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,009,654	5,777,184 ( 96.13 %)	0	96.13 %

Name	Equities	%	Valuation
CVI Holdings LLC 7.072 %	269,238	7.072 %	93 156 $
Allen Baharaff 5.983 %	227,790	5.983 %	78 815 $
Walleye Capital LLC 3.031 %	115,400	3.031 %	39 928 $
Morgan Stanley Capital Services LLC 2.166 %	82,468	2.166 %	28 534 $
Two Sigma Advisers LP 1.167 %	44,433	1.167 %	15 374 $
Two Sigma Investments LP 0.6177 %	23,516	0.6177 %	8 137 $
Citadel Securities GP LLC 0.2955 %	11,251	0.2955 %	3 893 $
Shmuel Nir 0.0857 %	3,263	0.0857 %	1 129 $
David Sidransky 0.0131 %	500	0.0131 %	173 $
Guy Nehemya 0.009850 %	375	0.009850 %	130 $

Galmed Pharmaceuticals Ltd.

16 Abba Hillel Road

5250608, Ramat Gan

+972 3 693 8448

http://galmedpharma.com

address Galmed Pharmaceuticals Ltd.(GLMD)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3787 USD

Average target price

1 USD

Spread / Average Target

+164.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GALMED PHARMACEUTICALS LTD.	-16.77%	2.28M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.48%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.91%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs